Check-Cap anticipates submitting data from this study for CE Marking in the first half of 2017 and initiating a U.S. pivotal trial in 2018.
"While the benefits of colorectal cancer screening are well documented in clinical literature and re-enforced in screening guidelines, there are several significant barriers, including resistance to bowel preparation, that continue to deter many of the average-risk population," said Bill Densel, CEO of Check-Cap. "We are developing the Check-Cap system to offer an alternative modality that may help increase screening rates by addressing the perceived drawbacks of existing methodologies that may serve as obstacles to screening for a significant segment of the population."
Ad Statistics
Times Displayed: 23122
Times Visited: 497 Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money
About Check-Cap
Check-Cap is a clinical-stage medical diagnostics company developing the world's first ingestible capsule system for preparation-free, minimally-invasive colorectal cancer screening.
The capsule utilizes innovative ultra-low dose X-ray and wireless communication technologies to scan the inside of the colon as it moves naturally, while the patient follows his or her normal daily routine. After passage, the system generates a 3D map of the inner surface of the colon which enables detection of polyps and cancer. Designed to increase the willingness of individuals to participate in recommended colorectal cancer screening, the Check-Cap system addresses many frequently-cited barriers, including laxative bowel preparation, invasiveness, and sedation. The Check-Cap system is currently not cleared for marketing in any jurisdiction.
Back to HCB News
